Since CCL2-neutralizing antibodies inhibit not only TAMs but also all the normal monocyte/macrophages in the body (e.g., bone marrow), which contributes to systemic side effects, we thought to utilize the tumor-homing ability of MSCs [13] and to develop a genetically-engineered cellular therapy. This evidence concerns the gene CCL2 and neoplasm.